Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

Swiss pharma giant Roche has announced the launch of the Roche Genentech Innovation Center Boston, USA, at Harvard’s Enterprise Research Campus in Allston which will further strengthen the ...

Visual acuity with both approaches was comparable and the device was efficacious and safe. The purpose of this study was to determine if continuous delivery of ranibizumab 100 mg/mL using the PDS with ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...